About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT00951210

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

The purpose of this study is to determine the safety of PLX-PAD, Intra-muscular injections for the treatment of CLI patients.

Lead sponsor: Pluristem Ltd.•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pluristem Ltd.

Age

40 - 81 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Diagnosis of critical limb ischemia defined as persistent, recurring ischemic rest pain for at least two (2) weeks, and/or ulceration or gangrene of the foot or toe, with ABI \< 0.6 or/and TBI \< 0.4
•2. Rutherford category 4-5
•3. Non candidate for revascularization or endovascular intervention based on unfavorable vascular anatomy or significant co-morbid medical conditions as confirmed by vascular study (e.g., angiogram, MRA) obtained within 3 months prior screening visit and signed approval of vascular surgeon. The decision to classify the subject as a non-candidate will be made by the investigator and confirmed by an independent third party vascular surgeon who is not participating in the study.
•4. In the opinion of the investigator, major amputation is not anticipated over a period of three (3) months.
•5. Those diabetic subjects who are on optimal diabetes medication, with an HbA1c \< 8%

Exclusion Criteria

•1. Uncontrolled hypertension (defined as diastolic blood pressure \> 110 mmHg or systolic blood pressure \> 180 mmHg during screening).
•2. Wounds with severity greater than Grade 2 on the Wagner Scale
•3. Life-threatening ventricular arrhythmia - except if an ICD is implanted - or unstable angina - characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged.
•4. ST segment elevation myocardial infarction and/or TIA/CVA within six (6) months prior to enrollment.Patients with severe congestive heart failure (i.e. NYHA Stage IV)
•5. In the opinion of the investigator, the patient is unsuitable for cellular therapy.

Related studies

BEETroot Juice to Reverse Functional Impairment in PAD

NCT05624125 · Peripheral Artery Disease

RECRUITINGEARLY Phase 1

Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease

NCT06212271 · Peripheral Artery Disease

Prevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease

NCT07283289 · Peripheral Artery Disease

MRI Guided Management of Occlusive Peripheral Arterial Disease

NCT06782100 · Peripheral Vascular Diseases

RECRUITINGPhase 3

A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)

NCT06656988 · Peripheral Vascular Diseases, Kidney Diseases

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 27, 2015Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment12

Start dateAug 2009

Last updatedMay 27, 2015

Condition

Peripheral Artery Disease Peripheral Vascular Disease Critical Limb Ischemia

Locations shown

Cardiology PC

Birmingham, Alabama

Duke University Medical Center

Durham, North Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 27, 2015Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions